Titre:	Serum levels of matrix metalloproteinase-1 in Brazilian patients with benign prostatic hyperplasia or prostate cancer
Auteur(s):	El-Chaer, William Khalil Tonet-Furioso, Audrey Cecília Morais Junior, Gilberto Santos Souza, Vinícius Carolino de Avelar, Gleiciane Gontijo Henriques, Adriane Dallanora Moraes, Clayton Franco Nóbrega, Otávio de Tolêdo
metadata.dc.identifier.orcid:	https://orcid.org/0000-0003-1511-0387 https://orcid.org/0000-0003-1775-7176
metadata.dc.contributor.affiliation:	Universidade de Brasília Universidade Católica de Brasília Universidade de Brasília Universidade de Brasília Universidade de Brasília Universidade de Brasília Universidade de Brasília Universidade Católica de Brasília Universidade de Brasília
Assunto::	Próstata - câncer Próstata - doenças Hiperplasia
Date de publication:	5-mai-2020
Editeur:	Hindawi
Référence bibliographique:	EL-CHAER, William Khalil et al. Serum levels of matrix metalloproteinase-1 in Brazilian patients with benign prostatic hyperplasia or prostate cancer. Current Gerontology and Geriatrics Research, [S. l.], v. 2020, Article ID 6012102, 7 p. DOI: https://doi.org/10.1155/2020/6012102. Disponível em: https://www.hindawi.com/journals/cggr/2020/6012102/. Acesso em: 22 jan. 2024.
Abstract:	Metalloproteinases (MMPs) are involved in metastatic tumor processes, with changes in circulating levels detected in several cancer types. Here, we compare serum concentrations of metalloproteinase-1 (MMP-1) across individuals clinically diagnosed with prostate cancer (PCa) or benign prostatic hyperplasia (BPH), correcting results for the rs495366 single nucleotide polymorphism (SNP) that predisposes to differential MMP-1 levels. 196 men aged ≥50 years were followed at a university hospital urology outpatient clinic, with clinical, anthropometric, and rectal examinations performed by one urologist. Blood samples obtained prior to any clinical intervention provided baseline MMP-1 and total/free PSA levels as well as metabolic, hormonal, and inflammatory markers. +e SNP was genotyped by real-time PCR. Participants with medical and/or laboratory profile compatible with malignancy composed the PCa group when confirmed by the Gleason scale. As expected, A-allele homozygotes showed reduced levels of MMP-1. Genotype-adjusted analyses revealed the mean MMP-1 level as 2-fold higher in PCa carriers compared to BPH patients. No other differences were found according to the prostatic condition or genotypic distribution, except for the expected raise in total and free PSA levels in PCa. In conclusion, increased serum levels of MMP-1 were observed in this context of prostatic malignancy compared to a benign phenotype, regardless of a genetic influence.
metadata.dc.description.unidade:	Faculdade UnB Ceilândia (FCE) Faculdade de Ciências da Saúde (FS) Faculdade de Medicina (FM)
metadata.dc.description.ppg:	Programa de Pós-Graduação em Ciências da Saúde Programa de Pós-Graduação em Ciências Médicas
Licença::	Copyright © 2020 William Khalil El-Chaer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
DOI:	https://doi.org/10.1155/2020/6012102
Collection(s) :	Artigos publicados em periódicos e afins

Tous les documents dans DSpace sont protégés par copyright, avec tous droits réservés.